Journal article
Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021
Abstract
The Pfizer-BioNTech COVID-19 vaccine (BNT162b2) is a lipid nanoparticle-formulated, nucleoside mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. Vaccination with the Pfizer-BioNTech COVID-19 vaccine consists of 2 intramuscular doses (30 μg, 0.3 mL each) administered 3 weeks apart. In December 2020, the vaccine was granted Emergency Use Authorization (EUA) by the Food and Drug Administration …
Authors
Dooling K; Gargano JW; Moulia D; Wallace M; Rosenblum HG; Blain AE; Hadler SC; Plumb ID; Moline H; Gerstein J
Journal
MMWR Morbidity and Mortality Weekly Report, Vol. 70, No. 38, pp. 1344–1348
Publisher
Centers for Disease Control MMWR Office
DOI
10.15585/mmwr.mm7038e2
ISSN
0149-2195